Interleukin-18 (IL-18), also known as interferon-gamma-inducing factor (IGIF), is a pro-inflammatory cytokine belonging to the IL-1 family of cytokines. The IL18 gene encodes a 24 kDa precursor protein (pro-IL-18) that is proteolytically cleaved by caspase-1 to produce the mature, biologically active 18 kDa form. IL-18 is constitutively expressed across multiple tissue types, including immune cells (macrophages, dendritic cells, and Kupffer cells), epithelial cells, and importantly, microglial cells within the central nervous system. The protein exists in both membrane-bound and secreted forms, allowing for local and systemic immunomodulatory effects. Unlike many other cytokines, IL-18 remains relatively stable in circulation and accumulates in tissues, making it a persistent immunological signal.
Function and Biology
...
IL-18 Protein
Overview
Interleukin-18 (IL-18), also known as interferon-gamma-inducing factor (IGIF), is a pro-inflammatory cytokine belonging to the IL-1 family of cytokines. The IL18 gene encodes a 24 kDa precursor protein (pro-IL-18) that is proteolytically cleaved by caspase-1 to produce the mature, biologically active 18 kDa form. IL-18 is constitutively expressed across multiple tissue types, including immune cells (macrophages, dendritic cells, and Kupffer cells), epithelial cells, and importantly, microglial cells within the central nervous system. The protein exists in both membrane-bound and secreted forms, allowing for local and systemic immunomodulatory effects. Unlike many other cytokines, IL-18 remains relatively stable in circulation and accumulates in tissues, making it a persistent immunological signal.
Function and Biology
IL-18 functions as a multifunctional cytokine with pleiotropic effects on immune cell activation and differentiation. The protein signals through a heterodimeric receptor complex composed of IL-18 receptor alpha (IL-18Rα) and IL-18 receptor beta (IL-18Rβ, also called IL-1RAcP). Binding to this receptor activates downstream signaling through MyD88-dependent pathways, leading to NF-κB and MAPK activation. In immune cells, IL-18 synergizes with IL-12 to promote interferon-gamma (IFN-γ) production from T cells and natural killer cells, thereby amplifying Th1-mediated immune responses. IL-18 also promotes IL-2 and TNF-α secretion and enhances cytotoxic T lymphocyte activity. The cytokine modulates both innate and adaptive immunity, acting as a bridge between these two immune compartments. Additionally, IL-18 participates in inflammasome-mediated pathways, particularly through NLRP3 inflammasome activation, which reciprocally activates caspase-1 for further IL-18 maturation, creating a potential amplification loop.
Role in Neurodegeneration
IL-18 has emerged as a critical mediator in multiple neurodegenerative conditions. In Alzheimer's disease, elevated IL-18 levels correlate with amyloid-beta accumulation and tau pathology, suggesting a role in disease progression. The cytokine promotes neuroinflammation through microglial activation, perpetuating a cycle of amyloid-beta phagocytosis impairment and neuronal dysfunction. In Parkinson's disease, IL-18 contributes to dopaminergic neuron loss through microglial-mediated neuroinflammation and enhancement of pro-inflammatory Th1 responses. Cerebrospinal fluid IL-18 levels show elevation in Parkinson's patients and correlate with disease severity. In amyotrophic lateral sclerosis (ALS), IL-18 participates in motor neuron degeneration both through direct effects and by promoting pro-inflammatory T cell responses. Elevated IL-18 in ALS patients associates with more rapid disease progression and shorter survival. In Huntington's disease, IL-18 amplifies striatal neuroinflammation and excitotoxic mechanisms. The cytokine also plays roles in other neurodegenerative conditions including multiple sclerosis and neuroinflammatory sequelae of traumatic brain injury.
Molecular Mechanisms
IL-18 promotes neurodegeneration through multiple interconnected mechanisms. Microglial IL-18 production is activated by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) released from degenerating neurons, including amyloid-beta and misfolded proteins. NLRP3 inflammasome activation, which processes pro-IL-18 to mature IL-18, is triggered by these neuronal danger signals. Mature IL-18 then acts on neighboring microglia and infiltrating immune cells, amplifying pro-inflammatory cytokine production including TNF-α, IL-1β, and IL-6. These cytokines directly damage neuronal integrity through NMDA receptor overstimulation, oxidative stress generation, and mitochondrial dysfunction. IL-18 also promotes Th1 differentiation of infiltrating T cells, perpetuating CNS neuroinflammation through IFN-γ production. In certain contexts, IL-18 suppresses regulatory T cells and anti-inflammatory responses, shifting the immune balance toward neurodestructive pathways.
Clinical and Research Significance
IL-18 serves as a biomarker for neuroinflammatory status in multiple neurodegenerative diseases. Cerebrospinal fluid and serum IL-18 levels are increasingly recognized as correlates of disease activity and progression. Therapeutic targeting of IL-18 through neutralizing antibodies, IL-18 binding protein administration, or inflammasome inhibition represents an emerging treatment strategy. Several experimental studies demonstrate that IL-18 neutralization or genetic deletion reduces neuropathology and behavioral deficits in animal models of neurodegeneration. Clinical trials investigating IL-18 antagonism are underway for select conditions.